




Comparative serological assays for the study of H5 and H7 avian influenza viruses. 
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The nature of influenza virus to randomly mutate and evolve into new types is an important challenge 
in the control of influenza infection. It is necessary to monitor virus evolution for a better understanding 
of the pandemic risk posed by certain variants as evidenced by the highly pathogenic avian influenza 
(HPAI) viruses. This has been clearly recognized in Egypt following the notification of the first HPAI 
H5N1 outbreak. The continuous circulation of the virus and the mass vaccination programme 
undertaken in poultry has resulted in a progressive genetic evolution and a significant antigenic drift 
near the major antigenic sites. In order to establish if vaccination is sufficient to provide significant 
intra- and inter-clade cross-protection, lentiviral pseudotypes derived from H5N1 HPAI viruses 
(A/Vietnam/1194/04, A/chicken/Egypt-1709-01/2007) and an antigenic drift variant (A/chicken/Egypt-
1709-06-2008) were constructed and used in pseudotype-based neutralization assays (pp-NT). Pp-NT 
data obtained was confirmed and correlated with HI and MN assays. A panel of pseudotypes 
belonging to influenza Group 1 and 2, with a combination of reporter systems, was also employed for 
testing avian sera in order to support further application of pp-NT as a valid assay alternative that can 
improve avian vaccination efficacy testing, vaccine virus selection, and the reliability of reference sera. 
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Egypt faced its first H5N1 outbreak in 2006 where a highly pathogenic avian influenza (HPAI) virus was 
detected in poultry [1]. The strategy used by the Egyptian authorities to mitigate this relied on vaccinating 
poultry, depopulating infected areas, and increasing awareness and biosecurity levels. Despite these efforts, 
by 2008 the H5N1 virus had become endemic and vaccine-escape variants have emerged despite 
commercial poultry vaccines exhibiting protection in laboratory settings [2]. For each year, from 2009 through 
2012, Egypt has had more laboratory-confirmed human cases reported to the WHO than any other country, 
and global concern regarding Egyptian H5N1 influenza viruses is currently high, as some isolates have been 
reported to possess at least two mutations, of the 4 (or 5) needed to confer ferret-to-ferret airborne 
transmissibility [3]. Despite the mass vaccination program undertaken in poultry, the continuous circulation of 
the virus has resulted in a progressive genetic evolution and a significant antigenic drift with multiple 
mutations near the major antigenic sites [4]. To date, the WHO has identified 12 new H5N1 clades and the 
Egyptian clade 2.2.1 was further split into a new sub-clade 2.2.1.1 [5,6]. The past experience in Egypt has 
proved that controlling avian influenza in poultry is the primary method to reduce the human risk from 
infection, and monitoring virus evolution can be extremely important for understanding the pandemic risk 
posed by certain subtypes, especially those prone to antigenic drift mechanisms as evidenced by the genetic 
and antigenic divergence of H5N1 HPAI viruses in Egypt [7-9]. 
Furthermore, it has been highlighted as a priority to combine vaccination with the implementation of specific 
systems to detect early infection with low pathogenicity avian influenza (LPAI) viruses, and to study naturally 
acquired or vaccine induced immunity in avian species via appropriate diagnostic tools and serological 
surveillance [10,11]. Recent studies have stressed the need of reinforcing serological tests as an auxiliary 
tool to evaluate the potency of commercial vaccines and monitor vaccine-driven evolution of emerging 
variants and consequent choice of seed viruses [2]. This has been clearly recognized when the inactivated 
vaccine containing an H5 virus belonging to a different lineage to the Eurasian H5N1 (H5N2/Mexico) is being 
actively used in order to control the HPAI outbreak in Egypt from 2006 [12-14].  
As shown by our earlier study, the emergence of an Egypt H5N1 drift variant (circulating one year later from 
the first H5N1 outbreak) exhibited significantly decreased cross-reactivity by haemagglutination-inhibition 
(HI) and microneutralization (MN) assays against the Mexican vaccine seed strain [15]. This evidence, 
together with previous observations, has raised the important question of the mechanism of antigenic drift 




the assessment of vaccine efficacy and evaluation of cross-neutralizing capability of the vaccine concurrent 
with incremental virus escape from neutralizing antibodies is important [16]. 
There are currently a wide range of serological assays available for influenza; the choice is mainly based on 
the viral protein targeted, the level of specificity required (subtype specific or non-subtype specific tests), and 
also the laboratory facilities needed for certain strains [17]. Despite the complexity of the antibody response 
against influenza viruses, the standard serological tests such as HI and MN are routinely employed in avian 
influenza reference laboratories as promoted by the FAO/OIE (www.offflu.net) and WHO [18]. More recently, 
due to their wide applicability and sensitivity, pseudotype based neutralization (pp-NT) assays have been 
shown to be valid alternatives to these established methods for studying the serological profiles of highly 
pathogenic influenza viruses, vaccine-induced immunogenicity and serological cross-reactivity of 
haemagglutinins (HAs) from different clades [19-21]. Moreover, recent studies [22,23] have revealed that 
broadly cross-neutralizing antibodies binding to the stalk region of HA can be indirectly measured by HA pp-
NT assays and to a lesser extent by MN, but not by HI which only measures those antibodies that bind to the 
globular head and interfere with receptor binding [24-27]. This study reports on the screening of avian sera 
for antibodies elicited by LPAI and HPAI viruses and proposes a new perspective for the widening 
application and validation of pp-NT serological assays especially with the potential to streamline the 
screening of large sample sets collated from in-field sero-epidemiology studies and vaccination programmes 
[17]. Towards this aim, we have firstly constructed HA pseudotypes from an HPAI Egyptian H5N1 virus and 
its closely related antigenic drift variant for a comparative serological framework to study cross-strain 
immunity induced by a LPAI H5N2 vaccine. Subsequently in this study, the HA-pseudotype panel has been 
expanded in order to demonstrate their unique versatility (via the use of alternative reporter systems), 
reliability (by testing sera from naturally infected birds and reference sera) and proposing them as powerful 
tools to support in-field and laboratory-based avian serology.  
 
Materials and methods 
Plasmids and pseudotype virus production 
Lentiviral pseudotypes with HA envelope glycoproteins derived from the HPAI viruses H5N1 
(A/Vietnam/1194/04, A/chicken/Egypt/1709-1/2007 and A/chicken/Egypt/1709-6/2008) and H7 




(NA) (1 Unit/plate; Sigma) added post transfection in order to induce the release of HA-pseudotypes from the 
surface of producer cells [28-30]. H5 and H7 pseudotypes were produced by co-transfection of HEK-293T 
cells with a complex comprising HA-expression plasmids (pl.18-HA), the HIV type 1 gag-pol (pCMV-Δ8.91) 
and the firefly luciferase reporter constructs (pCSFLW) using Fugene 6 (Roche) that facilitates highly-
efficient DNA transport into cells [31-33]. Additionally green fluorescent protein (GFP) pseudotypes bearing 
H5 glycoproteins from A/Vietnam/1194/04 and A/chicken/Egypt 1709-1/2007 strains were generated by 
incorporation of GFP retroviral construct (pCSGW) as reporter [34-38]. Concurrently, a no-HA control was 
generated by co-transfection of producer cell lines with two plasmids, gag-pol pCMV-Δ8.91and pCSFLW. 
Serum samples 
Five panels of sera were evaluated in this study and were all provided by the FAO, OIE and National 
Reference Laboratory for Newcastle disease and Avian influenza, Istituto Zooprofilattico delle Venezie.  
Panel 1 consisted of 10 sera positive for antibodies to the LPAI H5N2 vaccine strain 
(A/chicken/Mexico/232/94/CPA) obtained from chickens vaccinated at 21 days of age and boosted after 3 
weeks with a commercially available inactivated vaccine, which has been used in previous studies [12,15]. 
Panel 2 consisted of 10 sera positive for H7 collected from turkeys during an Italian outbreak caused by an 
LPAI virus H7N3. Panel 3 consisted of 10 sera positive for H5 with stratified incremental HI titers (ranging 
from 1:4 to 1:2048) collected from chickens vaccinated with an inactivated adjuvanted H5N2 vaccine, and 
were used for comparative firefly luciferase and GFP-pseudotype neutralization assays. In order to test for 
influenza HA group-specific virus neutralization, panel 4, consisting of 16 reference hyperimmune sera 
produced against 16 influenza subtypes (from Group 1 and Group 2) were also provided. These antisera 
(H1N1, H2N3, H3N8, H4N8, H5N1, H6N2, H7N3, H8N4, H9N2, H10N1, H11N9, H12N5, H13N6, H14N5, 
H15N9, H16N2) were produced in specific pathogen-free chickens by inoculation with viruses (inactivated by 
beta-propriolactone if HPAI viruses) as described previously [12]. A panel of 41 negative sera (Panel 5) 
confirmed by Agar Gel Immunodiffusion assay (AGID) and Enzyme-linked immunosorbent assay (ELISA) 
were also employed. 
HI and MN assays 
All the sera collected from vaccinated chickens were evaluated using standard protocols for HI and MN 




assays were also carried out for the H5- and H7-positive serum panels using the test antigens: H5N2 
(homologous to the Mexican LPAI vaccine) and H7N1 (A/Starling/Africa/985/79) respectively. Standard 
protocols were followed for both assays as described previously [15,39].  For the 41 negative sera a titer of 2 
was assigned when tested by HI. 
Firefly luciferase pp-NT assay 
For this assay, firefly luciferase pseudotypes bearing HAs from HPAI H5 (A/Vietnam/1194/04, 
A/chicken/Egypt/1709-1/2007, A/chicken/Egypt/1709-6/2008) and the HPAI H7 strain 
(A/chicken/Italy/13474/99) were used. Two-fold serial dilutions of serum samples were mixed with an equal 
volume of pseudotype virus resulting in 5x10
5
 relative light units (RLUs) after 48hrs under standard 
conditions. After a 1 hour-incubation at 37°C, 1x10
4
 HEK-293T cells were added to each well of a 96-well-
flat-bottomed culture plate and RLUs were evaluated after 48hr incubation with a luminometer (Promega Glo 
Max 96) using the Bright-Glo substrate (Promega). To measure neutralization activity, the 50% and/or 90% 
inhibitory dose (IC90) was determined as the serum dilution resulting in a 50% and/or 90% reduction of a 
single round of infection (reporter gene-mediated signal) [28,29,40]. All the results were compared to control 
wells containing virus alone, with the RLUs from cell-only wells subtracted from all the readings. Additionally, 
41 negative sera were also tested by using firefly luciferase pseudotypes (A/Vietnam/1194/04, 
A/chicken/Egypt/1709-1/2007, A/chicken/Egypt/1709-6/2008). 
GFP pp-NT assay 
The pp-NT assay was additionally performed using pseudotypes bearing HA from HPAI A/Vietnam/1194/04 
and A/chicken/Egypt 1709-1/2007 strains using a packaging construct with GFP reporter gene, and the GFP 
pp-NT assay was essentially performed as described previously [29,31]. In order to determine, for each 
strain, the amount of HA-pseudotyped virus required for this assay, complete medium was dispensed into 
each well of a clear 96-well flat-bottomed plate and 8 rows of 2-fold serial dilutions of the initial virus stock 
were prepared, followed by the addition of 50 µl of HEK-293T cells to each well. 3 days post infection, GFP 
expression was monitored using fluorescence microscopy. Normally 3 random fields of view are used to 
score the overall fraction of GFP-expressing cells and the volume of HA-pseudotyped virus used for the 
assay was calculated by choosing the reciprocal pseudotype virus dilution that corresponds to the amount 




fluorescence expressed by the percentage of green cells in the presence of serum. Sera with no presence of 
neutralizing antibodies, or negative sera were defined as 100% green cells or high GFP expression.  
Statistical analysis 
The estimation of pseudotype transduction titers was performed using Excel
TM
 software where pseudotype 
titers obtained at each of a range of dilution points were expressed as RLU/ml and the arithmetic mean was 
calculated by GrapdPad Prism (version 5, GraphPad Software, San Diego, CA, USA). Statistical analyses 
were also undertaken for the analysis of pp-NT assays using GraphPad.  Pp-NT titers were normalized and 
IC50 and IC90 values were calculated by dose-response inhibition analysis. In order to assess correlation 
between pp-NT, HI and MN, antibody titers were log10 transformed and Pearson’s correlation analysis was 
used. 
Results  
The initial aim of the present study was to study, via a comparative serological approach, the profile, 
described in our earlier study [15], of influenza H5N1 subclade 2.2.1 A/chicken/Egypt/1709-1/07 virus and its 
antigenic drift variant belonging to subclade 2.2.1.1 A/chicken/Egypt/1709-6/08 in order to confirm the 
reliability of pp-NT results when employed in parallel with standard HI and MN tests. Subsequently, we 
investigated if pseudotypes bearing HPAI H5 and H7 are accurately able to accurately detect neutralizing 
antibody responses elicited by LPAI H5 and H7 avian influenza viruses with the flexibility of using different 
reporter genes expressed by lentiviral vectors pseudotyped with influenza HA glycoproteins. In order to show 
the validity and robustness of the pp-NT method for its application to large-scale serological analyses the 
results obtained by pp-NT assays were compared with HI and MN tests.  
Panel H5 positive (collected from LPAI H5N2 A/chicken/Mexico/232/94 vaccine trial)  
Neutralizing antibodies were measured using firefly luciferase HPAI H5 influenza pseudotypes bearing HA 
glycoproteins derived from the HPAI viruses, clade 1 A/Vietnam/1194/04, A/chicken/Egypt 1709-1/2007 and 
A/chicken/Egypt/1709-6/2008. These pseudotypes were used in a neutralization assay for the detection of 
antibodies in a panel of 10 sera collected from chickens vaccinated with an LPAI strain belonging to a 
different lineage: A/chicken/Mexico/232/94/CPA (H5N2). Mexican-derived A/H5N2 inactivated vaccines were 
commonly used for vaccination programs in poultry farms, as undertaken in Egypt, where the samples used 




sera, tested in duplicate against A/Vietnam/1194/04, A/chicken/Egypt 1709-1/2007 and the drift variant 
A/chicken/Egypt/1709-6/2008 (Table 1). 41 negative sera previously tested AI antibody free by ELISA and 
AGID assays (data not shown) were also found negative by H5N1 A/Vietnam/1194/04, A/chicken/Egypt 
1709-1/2007 and A/chicken/Egypt/1709-6/2008 HA pp-NT.  
 
 
Table1. IC90-neutralizing antibody titres tested by pseudotype-based neutralization assays for chickens 
immunized with the Mexican-derived H5N2 strain. 
 
In order to assess whether the results obtained with pp-NT assay mirrored those obtained with conventional 
assays (HI and MN) extensively used for influenza serology, a regression analysis on paired datasets was 
performed in order to measure the significance of correlation. The results of this analysis were supported by 
a highly statistically significant correlation (p< 0.001) between antibody titers obtained by HI, MN or pp-NT. 
As shown in the scatterplots, titers obtained via HI correlated strongly with titers obtained using clade 2.2.1 
A/chicken/Egypt 1709-1/2007 (r
2
= 0.6291) (Figure 1) and the drift variant A/chicken/Egypt/1709-6/2008 (r
2
= 
0.7972) (Figure 2). Similar levels of correlation were observed between pp-NT titres and MN titres for both 
Egyptian strains (Figure 3). 
 
                                      IC90 neutralizating antibody titres 
Sera no. A/Vietnam/1194/04 A/ck/Egypt 1709 -1/2007               A/ck/Egypt 1709-6/2008 
4822/V09-1 2560-5120 >81920 160-320 
4822/V09-3 2560-5120 20480-40960 80-160 
4822/V09-4 320-640 1280-2560 40-80 
4822/V09-5 2560-5120 10240-20480 80-160 
4822/V09-6 2560-5120 20480-40960 320-640 
4822/V09-7 2560-5120 >81920 640-1280 
4822/V09-8 1280-2560 40960-81920 80-160 
4822/V09-9 1280-2560 >81920 320-640 
4822/V09-10 2560-5120 5120-10240 80-160 
4822/V09-12 2560-5120 40960-81920 40-80 




Figure 1. Comparison of pp-NT with HI antibody titer. Scatterplots showing the correlation of antibody 
logarithmic titers measured by pp-NT (using A/chicken/Egypt/1709-1/2007) versus HI (tested against 








Figure 2.  Comparison of pp-NT with HI antibody titers. Scatterplots showing the correlation of antibody 
logarithmic titers measured by pp-NT (using A/chicken/Egypt/1709-6/2008) versus HI (tested against 







Figure 3. Comparison of pp-NT with MN antibody titers. Scatterplots showing the correlation of antibody 
logarithmic titers measured by pp-NT (using A/chicken/Egypt/1709-1/2007 and A/chicken/Egypt/1709-
6/2008) versus MN (tested against A/chicken/Egypt/1709-1/2007 and A/chicken/Egypt/1709-6/2008). 
 
 
Similar correlation parameters were observed between HI titers and clade 1 A/Vietnam/1194/04 pseudotype 
(Figure 4). 
Figure 4. Comparison of pp-NT with HI antibody titers. Scatterplots showing the correlation of IC90 pp 
measured by pp-NT (using A/Vietnam/1194/04) versus HI (tested against A/chicken/Hidalgo/28159-







Incremental HI positive H5 serum panel 
Measurement of neutralizing antibodies using GFP and firefly luciferase HPAI H5 pseudotypes 
In order to determine the reliability and the applicability of the pp-NT assay using different reporter systems, 
H5 A/Vietnam/1194/04 and A/chicken/Egypt 1709-1/2007 pseudotypes carrying the GFP were tested against 
a panel of sera positive by HI with incremental titers ranging from 1:8 to 1:2048. 3 sera (3929-1, 3929-9, 
3929-6) were scored as 100% neutralization activity with pp titers > 1:1280 (no GFP-expression was 
observed) and sera: 3930-19, 3931-26 and 3930-20 showed 50% neutralization activity at 1:80, 1:160, 1:320 
when tested against A/Vietnam/1194/04. IC50 values corresponding to titers around ≤ 1:40 were obtained for 
sera with HI titers lower than 1:32. For A/chicken/Egypt 1709-1/2007 pseudotypes a similar pattern was 
observed: 4 sera (3929-1, 3929-9, 3929-6, 3930-19) have shown complete neutralization; for 3 sera (3931-
26 and 3930-20, 3933-41) 50% neutralization activity was scored between 1:640 and 1:1280. For 2 sera 
(3933-42 and 3933-50) percentage values of 50% lay between 1:80 and 1:320.  
In order to support the quantitative results obtained using GFP-pseudotypes, the panel of sera was tested in 
parallel against firefly luciferase HA-pseudotype.  Pp-NT results were found to correlate strongly with HI 
showing a similar neutralization profile; however for sera with an HI titre lower than 1:32, it has not been 
possible to determine the respective pp-NT neutralization values when H5 A/Vietnam/1194/04 pseudotypes 
have been used (Table 2). 
Table 2. Comparison between pp-NT assays using different reporter systems (GFP and CSFLW luciferase) 
and HI tests. IC50-neutralizing antibody titres tested by A/Vietnam/1194/04 and A/Egypt 1709-01/07. 
 














3933-42 1:8 < 40 80-160 80-160 80-160 
3933-50 1:16 < 40 640-1280 160-320 80-160 
3933-41 1:32 < 40 640-1280 320-640 1280-2560 
3930-20 1:64 160-320 2560-5120 640-1280 2560-5120 
3931-26 1:128 80-160 640-1280 1280 5120-10240 
3930-19 1:256 40-80 2560-5120 > 1280 5120-10240 
3929-6 1:512 > 1280 >10240 > 1280 2560-5120 
3929-9 1:1024 > 1280 5120-10240 > 1280 > 10240 





Panel H7 positive (collected from an LPAI H7 outbreak in Italy)  
A panel of 10 sera collected from turkeys during an Italian epizootic caused by an LPAI H7 virus was tested 
by A/chicken/Italy/13474/99 HA-pseudotype assay and by HI using H7N1 (A/Starling/Africa/985/79) as 
antigen. All sera were positive by HI showing a panel of different titers and 10/10 closely correlate with titers 
obtained by pp-NT as shown in figure 5. 41 negative sera obtained from chickens previously tested AI 
antibody free by ELISA and AGID assay were found negative by H7 A/chicken/Italy/13474/99 pseudotype-
based assay. 
 
Figure 5. Comparison of pp-NT with HI antibody titers. Scatterplots showing the correlation of antibody 
logarithmic titers measured by pp-NT (using A/chicken/Italy/13474/99) versus HI (tested against 









Cross-reactivity of influenza HA Group 1 and 2 pseudotypes using a panel of avian reference sera against all 
16 HA subtypes 
 
In order to determine the extent of HA-group specific “hetero-subtypic” cross reactivity, we tested the ability 
of reference hyperimmune avian sera (raised against H1N1, H2N3, H3N8, H4N8, H5N1, H6N2, H7N3, 
H8N4, H9N2, H10N1, H11N9, H12N5, H13N6, H14N5, H15N9, H16N2) to neutralize pseudotypes produced 
with the Group 1 viruses belonging to different clades: H5 A/chicken/Egypt 1709-1/2007 and 
A/chicken/Egypt/1709-6/2008 and Group 2 virus: H7 A/chicken/Italy/13474/99. The quantity of H5 and H7 
pseudotypes was chosen in order to have a virus input around 1x10
5
 RLUs and the cross-neutralization 
activity for both subtypes was determined as the serum dilution resulting in 50% reduction of luciferase 
signal. Sera with IC50 titers equal to or below 1x10
1
 were considered not cross-reactive as shown in figure 6. 
It is notable that HA-influenza pseudotypes are able to detect cross-specific neutralization within Groups 1 
and 2, and with some variation observable, H5-pseudotypes show similar patterns of cross-reactivity. Both 
Group 1 H5 pseudotypes (A/chicken/Egypt/1709-1/2008 and A/chicken/Egypt/1709-6/2008) exhibited cross-
reactivity with sera generated against the subtypes H1N1, H2N3, H6N2 and H8N4. The Group 2 H7 
pseudotype (A/chicken/Italy/13474/99) exhibited cross-reactivity with sera generated against H3N8, H4N8, 
H10N1 and H15N9. As additional control, H5 and H7 pseudotypes were also tested against reference sera: 

















Figure 6. PP-NT assay showing the presence of cross-reactivity in avian reference sera between 1 and 2 
influenza Groups tested by H5 A/chicken/Egypt/1709-1/2008 and A/chicken/Egypt/1709-6/2008 and H7 
A/chicken/13474/Italy/1999. Values corresponding to 50% neutralization (IC50) and with threshold serum 




















Discussion and Conclusions 
Up to 1995, there had been only three reports of avian influenza viruses infecting humans, in 1959, 1977 and 
1981. However, since 1996 there have been regular reports of natural infections of humans with avian 
influenza viruses [42]. Although these infections seem to have been limiting, with very little human to human 
transmission, the potential emergence of a virus capable of spread in the human population could occur via 
different mechanisms such as avian and human virus reassortment, re-circulation of existing subtypes and/or 
gradual adaptation of animal viruses to human transmission. The emergence of influenza viruses highlighted 
the ability of H5 and H7 subtypes to mutate from low to highly pathogenic after introduction into domestic 
poultry [43-45]. It follows that all HPAI viruses should have a LPAI progenitor and these incidents have 
raised concern about potential pandemics caused by viruses of the H5 and H7 subtypes or by any other 
avian influenza viruses with the potential to be transmitted to a variety of non-avian hosts including humans 
[44,46-48]. In some cases mutation seems to have taken place rapidly after introduction from the wild bird 
reservoir, in others the LPAI virus has circulated in poultry for months prior to mutating. The factors 
responsible and the mechanism by which LPAI virus mutates into HPAI virus remain unclear. However, it is 
reasonable to assume that the wider the circulation of LPAI in poultry, the higher the chance that mutation to 
HPAI will occur [42]. The recent implementation of active surveillance and vaccination policies with 
administration of appropriate vaccines in domesticated poultry has facilitated eradication of HPAI in many 
countries [49]. The control of infection in poultry and the validation of more sensitive and specific assays for 
detecting antibodies to avian influenza viruses in avian and non-avian species represents some of the main 
objectives for influenza experts from the animal and public health sectors [50]. The measurement of 
neutralizing antibody responses is critical for influenza sero-diagnosis, for the evaluation of novel vaccines 
and their effectiveness against drift variants arising as a consequence of vaccine pressure. The pp-NT assay 
represents a reliable and safe test to determine neutralizing antibody responses to all subtypes of influenza 
viruses [28,51]. This neutralization assay has shown high sensitivity and specificity when compared with the 
established serological tests, HI and MN, and has demonstrated wide applicability for antiviral and 
therapeutic antibody screening, and for the evaluation of vaccine efficacy.  Moreover, all these methods 
together can be used to evaluate how well the circulating isolates match the AI vaccine formulations in order 
to update the vaccine by using criteria similar to those used for human influenza vaccines [52]. Exploiting the 
inherent sensitivity of this assay, the aim of this study was to determine the levels of antibody response 




vaccinated with commercially available inactivated vaccine that has been used in poultry farms, or naturally 
infected with LPAI influenza viruses, and to show the correlation between pp-NT and the classical serological 
assays: HI and MN.  
A panel of H5 positive sera obtained from chickens vaccinated with an H5N2 A/chicken/Mexico/232/94/CPA 
strain were tested previously by us against the Egyptian H5N1 challenge strains (A/chicken/Egypt/1709-
1/2007, A/chicken/Egypt/1709-6/2008) and significant differences between these strains have been shown 
by HI and MN assays, most likely due to antigenic drift driven by the implementation of vaccination in poultry 
[15]. In parallel, pseudotypes bearing HPAI HAs were constructed (A/Vietnam/1194/04, A/chicken/Egypt 
1709-1/2007 and A/chicken/Egypt/1709-6/2008) [15,29]. Titers obtained via HI and MN correlated strongly 
(Figures 1-5) with those obtained using H5 pseudotypes (for A/chicken/Egypt/1709-1/2007: r
2
= 0.62 and for 
A/chicken/Egypt/1709-6/2008: r
2
= 0.78). When A/Vietnam/1194/04 pseudotypes were used the correlation 
was r
2
= 0.79 despite the fact that the HA used in this pp-NT assay was not antigenically matched as it 
belongs to a different clade. The rank of ordered neutralizing values obtained by pseudotypes mirrored the 
HI and MN assays. Interestingly, compared with HI and MN, the pp-NT overall gives higher numerical titers 
and appears to be more sensitive than MN. Recent studies have raised the possibility that the lower 
incorporation of HA spikes into retroviral pseudotypes, compared to the wild-type virus, makes pseudotypes 
more sensitive allowing the binding of antibodies not only on antigenic sites of HA surface but also on the HA 
stalk as shown in previously studies [24,53]. 
Similar results were obtained when a control panel of sera positive by HI against H7 were tested against 
A/chicken/Italy/13474/99 HA-pseudotypes showing not only the presence of a neutralizing antibody response 
against HPAI H7 in sera from chickens infected by an LPAI virus, but also a profile of neutralization that 
strongly correlates with HI. The pp-NT assay has the potential to be used in resource-limited countries 
where, the cost-benefit of this assay could be increased by the availability of different reporter systems, for 
example the use of GFP reporter instead of firefly luciferase. Additionally for laboratories lacking 
fluorescence or luciferase detection capability, β-galactosidase reporters could be used [31]. The results 
from this study revealed that the neutralization profile for pp-NT using a GFP reporter doesn’t show as clearly 
as firefly luciferase pp-NT the titer stratification (especially for sera that give low responses by HI). A 
comparative analysis of results obtained using the two different reporters on the same set of sera was 
performed and shows a clear correlation and a strong neutralizing profile although no correlate of protection 




Results for cross-reactivity analyses of Group 1 and 2 HA influenza pseudotypes against anti-sera from all 
16 HA subtypes sheds new light on the performance of the pp-NT assay using HI standards. Firstly, the 
specificity that can be gained by the use of influenza pseudotypes considering that the cut-off for negative 
sera was assigned for IC50 values equivalent or below 1X10
1
 and, H5 and H7 pseudotypes showed some 
degree of cross-reactivity with sera generated from viruses belonging to the same HA Groups and strong 
reactivity when H5 and H7 pseudotypes were tested against H5-H7 hyperimmune sera as shown in Figure 6. 
Furthermore, reactivity observed validates the reliability and the quality of OIE-FAO reference sera that 
represents a pre-requisite for the improvement of sero-diagnosis and can help to evaluate the effectiveness 
of vaccine strategies bearing in mind that an extensive library of reference sera for all influenza strains is an 
essential aspect for pandemic influenza preparedness [54]. It is likely that a new panel of reference sera will 
need to be prepared for use with pseudotype-based assays as they become more widely used in the future. 
The pp-NT assay is a valid surrogate for the more complex and time-consuming MN, and for HI. Influenza 
pseudotypes can be employed to screen antibody responses on the particle surface due to the fact that HA 
is the major antigen of the virus against which neutralizing antibodies are produced [55]. It will permit HA 
subtyping, antigenic tracking of virus evolution, and help to improve both the evaluation of vaccine 
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